Company intelligence / Profile preview

Sirtris Pharmaceuticals

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Before its 2008 acquisition by GlaxoSmithKline, Sirtris Pharmaceuticals was developing orally available small‑molecule activators of sirtuins, especially SIRT1, aiming to mimic calorie restriction for type 2 diabetes and other age‑related metabolic diseases; its lead programs (including resveratrol analogues such as SRT1460, SRT2104 and SRT2172) had reached preclinical and early clinical evaluation but did not advance to late‑stage development and were later reported to have significant assay and efficacy concerns.[5][4][9]

Therapeutic areas: ImmunologyEndocrinologyNeurologyPulmonologyMetabolic DisordersOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

GSK (strategic integration as an autonomous drug discovery unit after acquisition)[5][3]

Beyond the preview

Go deeper on Sirtris Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sirtris Pharmaceuticals.

Explore the full profile